Nephrol Dial Transplant (2002) 17: 408-412
© 2002 European Renal Association-European Dialysis and Transplant Association
Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose
Department of Nephrology, Hôpital Erasme, Brussels, Belgium
Background. Renal failure after ingestion of Chinese herbs between 1990 and 1992 was related to the replacement of Stephania tetrandra by Aristolochia fangchi (ST–AF), containing nephrotoxic and carcinogenic aristolochic acids. However, the relationship between ST–AF and renal failure is still a matter of debate. We therefore tested the impact of the ST–AF ingested dose on the progression of renal function deterioration.
Methods. Analysis of medical charts and prescriptions between 1990 and 1992 was carried out to determine the presence of risk factors for kidney failure and the cumulative dose of pill components. Individual progression rate of renal impairment was studied by the time-course of the inverse of blood creatinine level (1/Pcreat).
Results. Patients were divided into an end-stage renal disease (ESRD) group (n=44) and a chronic renal failure (CRF) group (n=27) according to their Pcreat at the time of this study. The mean number of risk factors (±SD) was equally distributed within both groups (1.50±0.18 vs 1.59±0.17, P=0.74). Patients from the ESRD group ingested significantly higher cumulative doses of ST–AF (192±13.1 g vs 138± 16.3 g), Magnolia officinalis, (80.1±6.3 g vs 59.8± 11.7 g), diethylpropion (14.7±1.4 g vs 10.0±1.4 g) and fenfluramine (14.1±1.6 g vs 8.7±1.3 g). In the ESRD group, some patients who had received steroids had a slower progression to ESRD than the others. In multiple regression analysis, ST–AF emerged as the only significant drug predicting the slope of the progression of renal failure. Moreover, hypothesizing a linear dose–response relationship, the risk of developing ESRD linearly increased with ST–AF doses.
Conclusions. The relationship between the cumulative ST–AF dose and the renal failure progression rate confirms that regular ingestion of Aristolochia sp. extracts is causally involved in the onset of chronic interstitial nephropathy leading to ESRD.
Keywords: Aristolochia species; Chinese herbs; chronic interstitial nephropathy; renal fibrosis; toxic nephropathy
Correspondence and offprint requests to: Joëlle Nortier, MD, PhD, Department of Nephrology, Hôpital Erasme, Route de Lennik 808, B-1070 Brussels, Belgium. Email: jnortier{at}ulb.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Pozdzik, I. J. Salmon, C. P. Husson, C. Decaestecker, E. Rogier, M.-F. Bourgeade, M. M. Deschodt-Lanckman, J.-L. Vanherweghem, and J. L. Nortier Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2480 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Nortier and J.-L. Vanherweghem For patients taking herbal therapy--lessons from aristolochic acid nephropathy Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1512 - 1517. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, Z. Liu, W. Hu, and L. Li Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy Human and Experimental Toxicology, February 1, 2005; 24(2): 41 - 47. [Abstract] [PDF]
|
|
|
|
|
|
S. H.-K. Lo, K.-L. Mo, K.-S. Wong, S.-P. Poon, C.-K. Chan, C.-K. Lai, and A. Chan Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1913 - 1915. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stiborova, E. Frei, B. Sopko, K. Sopkova, V. Markova, M. Lankova, T. Kumstyrova, M. Wiessler, and H. H. Schmeiser Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase Carcinogenesis, October 1, 2003; 24(10): 1695 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Unger, J. Nortier, M.-C. Muniz Martinez, D. Plein, J.-L. Vandenbossche, P. Vereerstraeten, and J.-L. Vanherweghem High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy Nephrol. Dial. Transplant., May 1, 2003; 18(5): 906 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. M. Martinez, J. Nortier, P. Vereerstraeten, and J.-L. Vanherweghem Steroid therapy in chronic interstitial renal fibrosis: the case of Chinese-herb nephropathy Nephrol. Dial. Transplant., November 1, 2002; 17(11): 2033 - 2034. [Full Text] [PDF]
|
|
|
|
|
|
C. van Ypersele de Strihou, M. Jadoul, M.-C. M. Martinez, J. Nortier, and J.-L. Vanherweghem Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1852 - 1852. [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Arlt, M. Stiborova, and H. H. Schmeiser Aristolochic acid as a probable human cancer hazard in herbal remedies: a review Mutagenesis, July 1, 2002; 17(4): 265 - 277. [Abstract] [Full Text] [PDF]
|
|